BioCryst Q2 2026 earnings: Licensing revenue lifts operating profit

BioCryst Pharmaceuticals (Nasdaq: BCRX) reported Q2 2026 revenue of $218.3 million, up 34% from $163.4 million, while diluted EPS rose to $0.30 from $0.02. For the quarter ended June 30, GAAP operating profit reached $98.5 million, although the increase was substantially supported by $55.7 million of revenue recognized from licensing navenibart’s European rights.

Core financial results

BioCryst’s GAAP operating margin was approximately 45.1%, compared with 18.2% a year earlier. Revenue growth combined with lower total operating expenses to lift net income to $78.4 million from $5.1 million.

ORLADEYO remained the largest revenue source, but license and other revenue accounted for nearly all of the year-over-year increase in total revenue.

The non-GAAP comparison excludes applicable items including stock-based compensation, the previously sold European ORLADEYO business, related transaction costs and acquisition-related expenses. The exact adjustments differ between periods.

ORLADEYO and pipeline progress

Reported ORLADEYO revenue increased only 1%, partly reflecting the October 2025 sale of BioCryst’s European ORLADEYO business. Excluding European revenue from the comparison, ORLADEYO revenue grew 10%, while total revenue increased 45% on a comparable basis.

After the quarter ended, BioCryst began shipping ORLADEYO oral pellets to pediatric patients during the week of August 3. The company reported 47 prescriptions year to date, with more than half having completed the prior-authorization process. CareMed is also scheduled to become the sole-source specialty pharmacy for ORLADEYO shipments beginning in Q3 2026.

In the pipeline, enrollment in the pivotal ALPHA-ORBIT study of navenibart was completed in June. BioCryst expects top-line results for the three-month and six-month dosing regimens in Q3 2027. The Phase 1 study of BCX17725 has entered a portion expected to enroll up to 12 Netherton syndrome patients for three months, with data anticipated by the end of 2026.

Licensing revenue drove most of the reported profit increase

Total revenue increased by $54.9 million year over year, while license and other revenue rose by $53.5 million. ORLADEYO contributed only about $1.4 million of incremental reported revenue, showing that the navenibart transaction was the main driver of the headline increase.

BioCryst received $70.0 million upfront for licensing navenibart’s European commercialization rights and recognized $55.7 million as Q2 revenue. The remaining upfront consideration will be recognized over the next several years. BioCryst is also eligible for as much as $275.0 million in regulatory and sales milestones, plus royalties of 18% to 30% on net sales.

Total operating expenses declined by $13.8 million to $119.8 million. Together, higher licensing revenue and lower expenses explain the $68.7 million increase in GAAP operating profit. ORLADEYO’s 10% comparable growth nevertheless indicates that the underlying product business performed better than the reported 1% increase suggests.

Profitability, cash flow and balance sheet

Research and development expense excluding stock-based compensation increased 37% to $46.5 million, primarily because of costs for the navenibart ALPHA-ORBIT study following the Astria acquisition. Sales and marketing expense excluding stock compensation declined 26% to $33.9 million on a reported basis but rose 2% after excluding European operations. General and administrative expense fell 30% to $20.8 million reported and 2% on a comparable basis.

Stock-based compensation declined to $14.7 million from $21.3 million. Below operating profit, BioCryst recorded $19.0 million of net other expense, including $21.7 million of interest expense.

BioCryst said Q2 cash flow remained positive even after excluding the $70.0 million licensing payment. Cash, cash equivalents, restricted cash and investments totaled $354.0 million at June 30. The balance sheet also included a $395.4 million secured term loan and a $426.8 million royalty financing obligation.

The profitable quarter should be distinguished from the six-month GAAP results. BioCryst reported a first-half net loss of $643.4 million, largely reflecting $697.8 million of acquired in-process research and development expense associated with the Astria transaction.

2026 guidance

BioCryst maintained its ORLADEYO outlook but increased total revenue guidance to include revenue from RAPIVAB and the navenibart European licensing agreement. The unchanged ORLADEYO range means the total revenue increase was not a raise to the company’s core product outlook.

The lower non-GAAP operating expense range was introduced in June following the decision to discontinue internal discovery programs and close the Birmingham facility by the end of 2026.

The operating expense outlook excludes stock-based compensation, restructuring costs and transaction-related costs.

Recent insider transactions

Over the reported six-month period, insider purchases totaled 919,856 shares across 24 transactions, while sales totaled 273,613 shares across four transactions. That produced net purchases of 646,243 shares; insiders were reported to hold 3.06 million shares, with net purchases representing 26.8%.

The latest ten individual records were stock awards rather than reported open-market trades. Nine were zero-value director grants on June 11, while one earlier grant carried a reported value of $11,244.

Because these recent transactions were compensation-related grants, they should not be interpreted in the same way as voluntary open-market purchases or sales.

Risks investors should watch

• Revenue mix: The Q2 increase in revenue and profit depended heavily on licensing revenue. The timing of future revenue recognition, milestones and royalties could make quarterly comparisons uneven.
• ORLADEYO execution: Achieving the unchanged full-year product guidance requires continued prescription momentum, a successful pediatric pellet rollout and an orderly transition to CareMed as the sole-source specialty pharmacy.
• Pipeline outcomes: Navenibart and BCX17725 remain investigational. Clinical timelines could change, and reported data may not support further development or approval.
• Restructuring execution: The lower expense outlook depends partly on winding down internal discovery and closing the Birmingham facility on the planned schedule and cost basis.
• Financing obligations: The secured term loan and royalty financing obligation create ongoing financing costs, as reflected in Q2 interest expense.

Conclusion

BioCryst’s second quarter combined comparable ORLADEYO growth with positive cash generation and substantially higher GAAP profitability. However, licensing revenue—not reported product growth—drove most of the financial increase. The next operating tests are execution against the unchanged ORLADEYO outlook, the pediatric launch and pharmacy transition, delivery of the reduced expense plan, and progress toward the stated clinical milestones.